Arch Biopartners
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.archbiopartners.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Arch Biopartners
Arch Biopartners is a therapeutic biotech company focused on developing innovative drugs for kidney injury and disease, specifically targeting acute kidney injury (AKI) and chronic kidney disease (CKD). Their lead drug candidates, LSALT peptide and Cilastatin, are currently in Phase II clinical trials, aiming to improve patient outcomes for those at risk of AKI. The company also explores novel therapies targeting IL-32, a cytokine linked to diabetic kidney disease, addressing a significant global health need. Arch's comprehensive approach positions it as a leader in kidney therapeutics, with potential applications extending beyond kidney conditions.Explore more
Arch Biopartners Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arch Biopartners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Arch Biopartners has new funding data
Congratulate Masked Content for being promoted to Masked Content at Arch Biopartners
Product Launch: Get notified when Arch Biopartners launches new products
Website visits: Recent activity has been detected on your website
Arch Biopartners, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Arch Biopartners is spiking on competitors!
Click to see if Arch Biopartners had a recent Job posting/layoffs
Earning: See what the market has to say on Arch Biopartners recently announced quarterly report
Check if Arch Biopartners has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Arch Biopartners as Masked Content
Find 3 more new buyers
Compare Similar Companies to Arch Biopartners
Compare insights from companies similar to Arch Biopartners, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arch Biopartners is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Arch Biopartners is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Arch Biopartners.
Arch Biopartners Tech Stack
A closer look at the technologies used by Arch Biopartners
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Person-Based
Person-Based
Arch Biopartners News & Media
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS).Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury in patients undergoing on-pump cardiac surgery.Arch Biopartners Closes Non-Brokered Private Placement
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”).Arch Biopartners Arranges Non-Brokered Private Placement
TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement offering of 1,000,000 common shares priced at $0.60 CAD per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”).
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arch Biopartners
Sign Up For FreeTo access detailed company insights
Arch Biopartners is a therapeutic biotech company focused on developing innovative drugs for kidney injury and disease, specifically targeting acute kidney injury (AKI) and chronic kidney disease (CKD). Their lead drug candidates, LSALT peptide and Cilastatin, are currently in Phase II clinical trials, aiming to improve patient outcomes for those a... Read More
